Key Stats for ISRG Stock
- Past-6-Month Performance: 7%
- 52-Week Range: $425 to $604
- Valuation Model Target Price: $733
- Implied Upside: 46%
Value your favorite stocks like Intuitive Surgical with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Intuitive Surgical stock is up about 7% over the past six months, recently trading near $504 per share as investors responded to strong procedure growth, accelerating adoption of da Vinci 5, and expanding recurring revenue.
Shares remain below the 52 week high of $604 but have steadily advanced as confidence in the company’s long-term growth profile improved.
The stock moved higher after the company delivered strong Q4 results that reinforced durable earnings momentum and clear 2026 visibility.
This week, Intuitive reported Q4 revenue of $2.87 billion, up 19%, with pro forma EPS rising to $2.53 from $2.21 as total procedures grew 18%.
For the full year, revenue increased 21% to $10.1 billion, total procedures rose 19% to more than 3.1 million, and free cash flow reached $2.5 billion.
CEO David Rosa said, “2025 was a strong year for Intuitive,” while management guided 2026 da Vinci procedure growth of 13% to 15% and projected gross margins of 67% to 68%, signaling continued platform expansion across da Vinci 5, SP, and Ion.
Institutional positioning has also remained active. Intech Investment Management increased its stake by 95.1% to 84,959 shares worth about $38 million, while LGT Capital Partners raised its position by 79.8% to 101,180 shares valued at $45 million.
Mitsubishi UFJ Asset Management held 857,315 shares worth about $383 million, representing roughly 0.24% of the company, and overall institutional ownership stands near 83.6%, reinforcing broad professional investor participation.
Some firms trimmed exposure, including TD Asset Management, which reduced its stake by 4% to 391,424 shares, and Dakota Wealth Management, which cut its position by 63.9%.
Even so, steady earnings execution and continued capital deployment across platforms have supported the stock’s six-month advance despite its premium valuation near 50x forward earnings.
See analysts’ growth forecasts and price targets for Intuitive Surgical (It’s free) >>>
Is ISRG Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 13.9%
- Operating Margins: 38.7%
- Exit P/E Multiple: 50.3x
Revenue is projected to grow from about $10.1 billion in 2025 to more than $18.2 billion by 2030, supported by consistent procedure growth, system placements, and recurring instrument and accessory sales.
Procedure volume remains the core driver, as each incremental surgery increases high-margin consumables revenue while strengthening hospital return on investment, which supports future system demand and pricing durability.
Operating margin expansion toward the high 30% range assumes increasing mix from da Vinci 5, scaling manufacturing efficiencies, and sustained leverage from recurring revenue, which already represents more than 80% of quarterly sales.
Growth in single-port procedures, continued Ion adoption, expansion into ambulatory surgery centers, and new indications such as cardiac procedures on da Vinci 5 add incremental growth vectors beyond core general surgery.
Based on these inputs, the model estimates a target price of $733, implying about 46% total upside from current levels near $504.
Over the next year, performance will be shaped by procedure growth consistency within the 13% to 15% range, da Vinci 5 utilization trends, international expansion, and margin resilience amid tariff pressures.
At current levels, Intuitive Surgical appears undervalued, with future returns tied to sustained procedure growth and recurring revenue leverage rather than multiple expansion alone.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does ISRG Stock Have From Here?
Investors can estimate Intuitive Surgical potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See Intuitive Surgical true value, or any stock’s, in under 60 seconds (Free with TIKR) >>>
